Abstract
In discussions on breast cancer screening, much attention has been focussed on the possible morbidity generated by screening. Favourable effects like the prevention of advanced disease seem underestimated, probably because quantification is that difficult. To analyse the amount of care and treatment given to women with advanced breast cancer, we report on patients followed from first recurrence until death using patient files and national sources. A random sample of 60 female cases from computerised registries of two cancer centres and a sample of 20 cases from a non-computerised hospital registry was taken. A total of 68 patient files were sufficiently documented. A woman with advanced breast cancer is estimated to have a 39% loss in utility compared to a healthy woman (range 27-45%). Hormonal treatment is the main modality during 14 and chemotherapy during 4 months. Total medical cost from diagnosis of advanced disease until death amounts to 17,100 US dollars, or 21,000 when including extramural cost. The effect of breast cancer screening by preventing the occurrence of advanced disease is quantified. The resulting gain in quality of life contributes 70% of the total gain in quality of life. In the long run, almost half of the annual cost of screening will be offset by savings in the cost for advanced disease. Only the changes in palliative surgery and/or radiotherapy will be small in contrast to primary treatment changes. Besides the mortality reduction, screening is justified by the improvements in quality of life and cost savings for women prevented from reaching advanced disease.
Full text
PDF





Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andersson I., Aspegren K., Janzon L., Landberg T., Lindholm K., Linell F., Ljungberg O., Ranstam J., Sigfússon B. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ. 1988 Oct 15;297(6654):943–948. doi: 10.1136/bmj.297.6654.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baker M. S., Kessler L. G., Urban N., Smucker R. C. Estimating the treatment costs of breast and lung cancer. Med Care. 1991 Jan;29(1):40–49. doi: 10.1097/00005650-199101000-00004. [DOI] [PubMed] [Google Scholar]
- Cassileth B. R., Lusk E. J., Strouse T. B., Miller D. S., Brown L. L., Cross P. A., Tenaglia A. N. Psychosocial status in chronic illness. A comparative analysis of six diagnostic groups. N Engl J Med. 1984 Aug 23;311(8):506–511. doi: 10.1056/NEJM198408233110805. [DOI] [PubMed] [Google Scholar]
- Dixon A. R., Ellis I. O., Elston C. W., Blamey R. W. A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer. 1991 Apr;63(4):634–635. doi: 10.1038/bjc.1991.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dixon J. M., John T. G. Morbidity after breast biopsy for benign disease in a screened population. Lancet. 1992 Jan 11;339(8785):128–128. doi: 10.1016/0140-6736(92)91042-7. [DOI] [PubMed] [Google Scholar]
- Ellman R., Angeli N., Christians A., Moss S., Chamberlain J., Maguire P. Psychiatric morbidity associated with screening for breast cancer. Br J Cancer. 1989 Nov;60(5):781–784. doi: 10.1038/bjc.1989.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Holli K., Hakama M. Treatment of the terminal stages of breast cancer. BMJ. 1989 Jan 7;298(6665):13–14. doi: 10.1136/bmj.298.6665.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hopwood P., Howell A., Maguire P. Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. Br J Cancer. 1991 Aug;64(2):349–352. doi: 10.1038/bjc.1991.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nerenz D. R., Love R. R., Leventhal H., Easterling D. V. Psychosocial consequences of cancer chemotherapy for elderly patients. Health Serv Res. 1986 Feb;20(6 Pt 2):961–976. [PMC free article] [PubMed] [Google Scholar]
- Patel J. K., Nemoto T., Vezeridis M., Petrelli N., Suh O., Dao T. L. Does more intense palliative treatment improve overall survival in metastatic breast cancer patients? Cancer. 1986 Feb 1;57(3):567–570. doi: 10.1002/1097-0142(19860201)57:3<567::aid-cncr2820570328>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
- Perez J. E., Machiavelli M., Leone B. A., Romero A., Rabinovich M. G., Vallejo C. T., Bianco A., Rodriguez R., Cuevas M. A., Alvarez L. A. Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncológico Cooperativo del Sur. Am J Clin Oncol. 1990 Aug;13(4):294–298. doi: 10.1097/00000421-199008000-00005. [DOI] [PubMed] [Google Scholar]
- Powles T. J., Coombes R. C., Smith I. E., Jones J. M., Ford H. T., Gazet J. C. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet. 1980 Mar 15;1(8168 Pt 1):580–582. doi: 10.1016/s0140-6736(80)91066-1. [DOI] [PubMed] [Google Scholar]
- Roberts M. M., Alexander F. E., Anderson T. J., Chetty U., Donnan P. T., Forrest P., Hepburn W., Huggins A., Kirkpatrick A. E., Lamb J. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet. 1990 Feb 3;335(8684):241–246. doi: 10.1016/0140-6736(90)90066-e. [DOI] [PubMed] [Google Scholar]
- Roberts M. M. Breast screening: time for a rethink? BMJ. 1989 Nov 4;299(6708):1153–1155. doi: 10.1136/bmj.299.6708.1153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tabar L., Fagerberg G., Duffy S. W., Day N. E. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health. 1989 Jun;43(2):107–114. doi: 10.1136/jech.43.2.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tomin R., Donegan W. L. Screening for recurrent breast cancer--its effectiveness and prognostic value. J Clin Oncol. 1987 Jan;5(1):62–67. doi: 10.1200/JCO.1987.5.1.62. [DOI] [PubMed] [Google Scholar]
- Wald N., Frost C., Cuckle H. Breast cancer screening: the current position. BMJ. 1991 Apr 6;302(6780):845–846. doi: 10.1136/bmj.302.6780.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Haes J. C., de Koning H. J., van Oortmarssen G. J., van Agt H. M., de Bruyn A. E., van Der Maas P. J. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 1991 Oct 21;49(4):538–544. doi: 10.1002/ijc.2910490411. [DOI] [PubMed] [Google Scholar]
- de Haes J. C., van Knippenberg F. C., Neijt J. P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990 Dec;62(6):1034–1038. doi: 10.1038/bjc.1990.434. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Koning H. J., van Ineveld B. M., van Oortmarssen G. J., de Haes J. C., Collette H. J., Hendriks J. H., van der Maas P. J. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer. 1991 Oct 21;49(4):531–537. doi: 10.1002/ijc.2910490410. [DOI] [PubMed] [Google Scholar]
- de Koning H. J., van Oortmarssen G. J., van Ineveld B. M., van der Maas P. J. Breast cancer screening: its impact on clinical medicine. Br J Cancer. 1990 Feb;61(2):292–297. doi: 10.1038/bjc.1990.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Oortmarssen G. J., Habbema J. D., van der Maas P. J., de Koning H. J., Collette H. J., Verbeek A. L., Geerts A. T., Lubbe K. T. A model for breast cancer screening. Cancer. 1990 Oct 1;66(7):1601–1612. doi: 10.1002/1097-0142(19901001)66:7<1601::aid-cncr2820660727>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
